Welcome to our dedicated page for Rxsight SEC filings (Ticker: RXST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RxSight, Inc. (RXST) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. RxSight is an ophthalmic medical device company focused on its Light Adjustable Lens system for cataract surgery patients, and its filings offer detailed insight into how this business is developing.
RxSight uses current reports on Form 8-K to announce material events. Recent 8-K filings have covered topics such as quarterly and interim financial results, including revenue composition between Light Adjustable Lenses and Light Delivery Devices, and leadership changes involving the Chief Financial Officer and Board of Directors. These filings often reference accompanying press releases that provide additional context on procedure volumes, installed base metrics for Light Delivery Devices, and guidance ranges.
Other SEC reports, such as quarterly and annual filings (Forms 10-Q and 10-K), typically include more extensive information on RxSight’s single reportable segment, which encompasses research and development, manufacturing, and sale of Light Adjustable Lenses and related capital equipment. They also describe operating expenses, cash and investment balances, and non-GAAP measures like adjusted net earnings (loss) that exclude stock-based compensation.
On this page, Stock Titan surfaces RxSight’s SEC filings in real time as they become available from EDGAR and pairs them with AI-powered summaries. These summaries are designed to highlight key points—such as changes in operating performance, governance updates, or material agreements—so readers can quickly understand the significance of each document without reading every line.
Investors, analysts, and other interested readers can use this RXST filings page to review Forms 8-K, 10-Q, 10-K, and related exhibits, as well as to monitor ongoing disclosures about RxSight’s Light Adjustable Lens business, financial condition, and corporate governance.
Artisan Partners has disclosed a significant stake in RxSIGHT, Inc. Investment adviser Artisan Partners Limited Partnership and its affiliated parent entities report beneficial ownership of 2,157,264 shares of RxSIGHT common stock, representing 5.2% of the class, based on 41,116,640 shares outstanding as of 10/30/2025.
The group reports shared voting power over 1,955,441 shares and shared dispositive power over 2,157,264 shares, with no sole voting or dispositive power. The shares were acquired for discretionary clients of Artisan Partners Limited Partnership, whose clients receive dividends and sale proceeds, and none is known to hold more than 5% individually. The owners certify the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of RxSIGHT.
RxSight, Inc. reported new equity awards to Chief Financial Officer Mark Wilterding. On January 12, 2026, he received a stock option covering 258,770 shares of common stock at an exercise price of $10.09 per share. Twenty five percent of this option vests on January 11, 2027, with the remainder vesting in equal monthly installments over the following three years, contingent on continued service.
He also received 163,528 restricted stock units, each representing one share of common stock. One eighth of the RSUs will vest on February 28, 2026, with additional one-eighth portions vesting every six months on the last day of February and August over a four-year period, also subject to his continued service.
RxSight, Inc.’s Chief Financial Officer Mark Wilterding has filed an initial Form 3 reporting no share ownership. The filing states that no non-derivative or derivative securities of RxSight are beneficially owned as of the event date of January 11, 2026.
RxSight, Inc. filed an initial beneficial ownership report for Chief Customer Officer Gaines Scott as of 12/18/2025. Scott directly owns 11,167 shares of RxSight common stock. He also holds several stock options covering 22,917, 14,167, 9,999, 25,000, 18,285 and 25,000 shares at exercise prices ranging from $7.78 to $56.07, which vest monthly over four years so long as he remains a service provider under the company’s 2021 Equity Incentive Plan. In addition, he holds restricted stock unit awards for 4,500, 3,018, 7,500, 11,593 and 3,750 shares, which vest in scheduled installments on specified trading days between 2025 and 2029, also contingent on continued service.
RxSight, Inc. filed an 8-K to report two main updates. The company issued a press release with preliminary, unaudited financial and operational results for the fourth quarter and full year 2025, furnished as Exhibit 99.1 and not treated as filed for liability purposes.
The board appointed Mark Wilterding as Chief Financial Officer and principal financial and accounting officer, effective January 11, 2026, succeeding Shelley Thunen. His employment terms include a $550,000 annual base salary, an annual bonus opportunity of up to 65% of base salary, and equity grants consisting of an option to purchase 258,770 shares and 163,528 restricted stock units with four-year vesting schedules, all under the 2021 Equity Incentive Plan. He also entered into change in control severance and indemnification agreements consistent with other executive officers.
RxSight, Inc. reported that it has entered into a transition agreement and release of claims, as well as a consulting agreement, with its outgoing Chief Financial Officer and principal financial and accounting officer, Shelley Thunen. Under these agreements, she will provide certain transition services to support the company after her employment separation date.
The company stated that this Chief Financial Officer leadership transition does not affect its outlook or expectations for full-year 2025. RxSight also noted that it continues to execute on its strategic and operational priorities, indicating that its business plans and financial expectations remain intact despite the change in its finance leadership.
RxSight, Inc. reported lower quarterly sales and a wider loss while maintaining a strong cash position as it scales its light-adjustable intraocular lens business. For the three months ended September 30, 2025, sales were $30,340 (in thousands), down from $35,314 (in thousands) a year earlier, with gross profit of $24,227 (in thousands) and an operating loss of $12,178 (in thousands). Net loss was $9,816 (in thousands), or $0.24 per share, compared with a net loss of $6,338 (in thousands), or $0.16 per share.
For the first nine months of 2025, sales were $101,871 (in thousands) versus $99,713 (in thousands) in 2024, and net loss increased to $29,792 (in thousands) from $21,517 (in thousands). Cash, cash equivalents and short-term investments totaled $227,500 (in thousands) as of September 30, 2025, and management believes this will fund operations for at least 12 months, though it still expects ongoing operating losses.
RxSight had 1,109 Light Delivery Devices installed and approximately 276,000 Light Adjustable Lenses implanted since inception, reflecting continued commercial adoption. The company also disclosed consolidated securities class actions and shareholder derivative suits seeking unspecified damages related to its disclosures, which it contests and intends to defend vigorously.
RxSight, Inc. (RXST) furnished quarterly results via a current report. The company announced results of operations and financial condition for the three and nine months ended September 30, 2025, under Item 2.02. The information was furnished, not filed, meaning it is not subject to Section 18 liability and is not incorporated into other filings unless specifically referenced. A press release with the details is included as Exhibit 99.1, with the cover page interactive data tagged as Exhibit 104.
Insider purchases reported for RxSight, Inc. (RXST). On 09/25/2025 Co-President and Chief Operating Officer Ilya Goldshleger acquired 15,096 and 8,349 shares of common stock at $4.34 and $4.13 per share respectively, increasing his direct holdings to 65,691 shares. Separate stock option exercises or grants totaling 23,445 options at $4.34 and $4.13 were also reported. Holdings include 1,372 shares held indirectly by spouse.
RxSight, Inc. filed an amendment to update a prior report about the appointment of Raymond W. Cohen to its Board of Directors. The new filing explains that, on August 14, 2025, the board appointed Cohen to both the Compensation Committee and the Audit Committee, effective immediately.
After these changes, the Compensation Committee consists of Robert J. Palmisano (Chair), J. Andy Corley, Robert Warner, and Raymond W. Cohen. The Audit Committee consists of Julie B. Andrews (Chair), Juliet Tammenoms Bakker, Tamara R. Fountain, M.D., and Raymond W. Cohen.